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Abstract
■ A balance has to be struck between supporting distractor-
resistant representations in working memory and allowing those
representations to be updated. Catecholamine, particularly dopa-
mine, transmission has been proposed to modulate the balance
between the stability and flexibility of working memory represen-
tations. However, it is unclear whether drugs that increase cate-
cholamine transmission, such as methylphenidate, optimize this
balance in a task-dependent manner or bias the system toward
stability at the expense of flexibility (or vice versa). Here we dem-
onstrate, using pharmacological fMRI, that methylphenidate im-
proves the ability to resist distraction (cognitive stability) but
impairs the ability to flexibly update items currently held in work-
ing memory (cognitive flexibility). These behavioral effects were
accompanied by task-general effects in the striatum and opposite
and task-specific effects on neural signal in the pFC. This suggests
that methylphenidate exerts its cognitive enhancing and impair-
ing effects through acting on the pFC, an effect likely associated
with methylphenidate’s action on the striatum. These findings
highlight that methylphenidate acts as a double-edged sword,
improving one cognitive function at the expense of another,
while also elucidating the neurocognitive mechanisms underlying
these paradoxical effects. ■
INTRODUCTION
Methylphenidate is used to treat attention deficit hyper-
activity disorder (ADHD; Swanson et al., 1998) and is also
taken by healthy adults in the hope of improving aca-
demic and cognitive performance (Maher, 2008). Methyl-
phenidate acts by blocking the dopamine transporter
(Gatley et al., 1999; Ritz, Lamb, Goldberg, & Kuhar,
1987), leading to increased dopamine and noradrenaline
in pFC (Berridge et al., 2006) and increased dopamine in
striatal areas (Volkow et al., 2001).
Despite the widespread use of methylphenidate, char-
acterizing its precise cognitive effects has proved to be a
difficult task. For example, despite the well-known
dependence of working memory on catecholaminergic
tone (Berridge & Arnsten, 2013; Vijayraghavan, Wang,
Birnbaum, Williams, & Arnsten, 2007; Zahrt, Taylor,
Mathew, & Arnsten, 1997; Brozoski, Brown, Rosvold, &
Goldman, 1979), the effects of methylphenidate on work-
ing memory are variable (Ilieva, Hook, & Farah, 2015;
Smith & Farah, 2011). Some of this variability likely reflects
individual differences in dopamine release (Clatworthy
et al., 2009). However, the precise nature of the task de-
mands is now also known to contribute to the direction
and extent of catecholaminergic drug effects (Fallon
et al., 2015; Linssen, Sambeth, Vuurman, & Riedel, 2014;
Bari & Robbins, 2013; Floresco, 2013; Mehta, Manes,
Magnolfi, Sahakian, & Robbins, 2004; Cools, Barker, Sahakian,
& Robbins, 2001; Gotham, Brown, & Marsden, 1988).
Although much research on working memory focuses
on delay-related stabilization of memoranda, it is widely
recognized that attentional mechanisms—the gating and
selection of specific stimuli—play an integral part in de-
termining the life span and vivacity of remembered items
(Fallon, Zokaei, & Husain, 2016; Gazzaley & Nobre,
2012). A balance has to be struck between supporting
robust mental representations that are resistant to inter-
ference (cognitive stability) and allowing those represen-
tations to be sufficiently flexible to be updated (cognitive
flexibility; Braver & Cohen, 2000). Thus, although it may
be advantageous in certain contexts to keep hold of infor-
mation and protect it from distraction, it is also important
to efficiently update information that is no longer rele-
vant. However, the extent to which gating the entry of
items into working memory is affected by changes in cat-
echolaminergic tone and the neural locus of these effects
have not been examined. According to existing neuro-
computational models, methylphenidate, through modu-
lating dopamine levels, might have antagonistic effects
on the stability versus flexibility of mnemonic repre-
sentations (Durstewitz & Seamans, 2008; Hazy, Frank,
& O’Reilly, 2007), an idea that runs counter to its clinical
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usage, and the suggestion that methylphenidate acts as a
uniform cognitive enhancer.
The neural locus of any differential effect on stability ver-
sus flexibility is hotly contested.Dopaminehasbeenhypoth-
esized to modulate the balance between cognitive stability
and flexibility through acting on the pFC (Durstewitz &
Seamans, 2008), the striatum (Hazy et al., 2007), or through
there being a division of labor, with the frontal cortex pro-
moting stability and the striatum promoting flexibility
(Cools & D’Esposito, 2011). In particular the dorsal stria-
tum, and its modulation by dopamine, has been implicated
in updating (or preparing to update) items in working
memory (Fallon & Cools, 2014; Yu, FitzGerald, & Friston,
2013; Murty et al., 2011; Dahlin, Neely, Larsson, Backman,
& Nyberg, 2008; Hazy et al., 2007). This study sought to ad-
judicate between these hypotheses by examining whether
any effect of methylphenidate on the tradeoff between cog-
nitive stability and flexibility is accompanied by neural
changes in the frontal cortex and/or dorsal striatum using
pharmacological fMRI.
Although methylphenidate is assumed to act on cogni-
tive functions directly, there is another possibility: Meth-
ylphenidate may exert its effects on working memory
vicariously, via boosting the response to rewarding
events that subsequently alter the mnemonic functions
of the pFC. This hypothesis concurs generally with recent
observations that working memory allocation is value-
based (Chatham & Badre, 2013; Dayan, 2012; Dixon &
Christoff, 2012; Hazy et al., 2007). More directly, previ-
ously we have found that the reward-related BOLD signal
increase in the ventral striatum for an unexpected finan-
cial gain, compared with a loss, predicted its effect on
ignoring or updating items in working memory (Fallon
& Cools, 2014). Given that reward-related processing
in the ventral striatum is thought to be dopaminergic in
origin (Knutson & Gibbs, 2007), methylphenidate might
modify the ventral striatal response to gains versus losses,
which in turn exerts downstream effects on cognitive
control. Thus, we also assessed the hypothesis that meth-
ylphenidate affects cognitive control vicariously through
modulating ventral striatal reward response.
Using pharmacological fMRI, we examined the effect of
methylphenidate on a modified delay match-to-sample
task in a double-blind placebo-controlled crossover
study. The task was modified to include two additional
phases during the delay period between encoding and
probe (Figure 1). First, participants received an unexpected
outcome (gain, neutral, or loss) after playing a gamble.
Next they were presented with novel intervening stimuli,
which had to be either ignored or updated in working
memory.
METHODS
Participants
Twenty-four participants (11 men, 13 women) gave writ-
ten informed consent to take part in this study and were
compensated for participation (A130). Three partici-
pants were excluded (two due to incomplete data due
to scanner malfunction and one due to inability to per-
form task in the scanner; mean accuracy ∼38%). The re-
maining participants were aged between 19 and 28 years
(mean = 21.40 years).
Inclusion and Exclusion Criteria
Exclusion criteria for participation in the study were as
follows: uncorrected visual impairment (e.g., color
blindness), history of neurological or psychiatric disorder,
Figure 1. An illustration of the
modified delay match-to-sample
task used (Fallon & Cools,
2014). Participants were
presented with two stimuli
that always had to be encoded
(2000 msec). After a variable
delay period (2000–6000 msec),
a 1500-msec response screen
requested participants to make
a choice to receive a gain,
neutral, or loss outcome
(1000 msec). After another
variable delay period (2000–
6000 msec), participants were
presented with novel stimuli
(1000 msec) that had to be
ignored or used for working
memory updating (displacing
the original targets). A no-interference condition, in which only a fixation cross appeared (1000 msec), was included as a control condition. After
another variable delay period (2000–6000 msec), participants were presented with a probe item. Participants had to responding according to whether
the presented item matched or did not match one of those items in the same. In the present example, the correct answer would be a match
if the current trial was in the ignore or no-interference condition, but a nonmatch in the update condition. They had a maximum of 2000 msec
to respond.
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history of medical treatment to head or neck, history of
asthma, history of disorder that may affect metabolism or
circulation (diabetes, hypertension, cardiac arrhythmia),
currently taking over-the-counter medications, pregnancy,
metallic implants, current smoker, consumption of >20
units alcohol or 20 cigarettes per week, history of hard drug
use (e.g., heroin or cocaine), cannabis use <2 weeks
before testing and history, left-handedness, tattoos,
unremovable body piercings, claustrophobia, and frequent
gambling (e.g., casino, fruit machines).
Intake and Testing Procedures
Participants took part in an intake session, during which
they performed some baseline tests and were trained on
the tasks that they had to perform on each of the test
days. Participants were screened by a medical doctor
(NtH) to check for contraindications for taking methyl-
phenidate (family history of tics, etc.) and were screened
by a psychologist (MvdS) using the Mini International
Neuropsychiatric Interview (Sheehan et al., 1998) to
assess any history of psychiatric problems. Physiological
measurements (height, weight, pulse rate, and blood
pressure) and the following psychological measures
were also assessed: depression (Beck Depression Inven-
tory; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961),
trait anxiety (Spielberger Trait Anxiety Inventory;
Spielberger, Gorsuch, & Lushene, 1970), and ADHD
symptomatology (Pappas, 2006).
Pharmacological Design and Procedure
Participants were tested using a within-subject, double-
blind, placebo-controlled cross-over design on two sepa-
rate occasions, once after taking 20 mg methylphenidate
(Ritalin) and once after taking a placebo substance, with
the order counterbalanced across participants. This dose
was chosen as it has been found to exert cognitive effects
(Elliott et al., 1997; though see Linssen et al., 2011). The
drug and placebo sessions occurred with a minimum of a
1-week gap and a maximum of 4-week gap. Scanning took
place roughly 1 hr after drug administration.
Task Procedure
The task is a modified delay match-to-sample task and
has been fully described (Fallon & Cools, 2014; Figure 1).
Each trial contained four distinct phases separated by
three delay periods.
Encoding Phase
Participants were presented with the letter “T” in the
middle of the screen flanked by two computer-generated
“spirographs” of different colors. Note that every shape
was novel and had a different color (RGB value). The
presence of a “T” in the center of the screen indicated
that the stimuli had to be remembered as the “Target”
stimuli.
Outcome Phase
On the gain and loss trials, participants had to guess the
outcome of a coin toss by making a head or tails response
with their index or middle finger, respectively. Two screens
were then presented: a “LOSS” screen with a negative au-
ditory tone (“horn”; a loss ofA1); or a “WIN” screen with a
positive auditory tone (cash register; a win of A1). Gains
and losses did not depend on performance, were equally
frequent, and did not lead to a net loss/gain. In a control
condition, participants just made a left or right response,
after which they saw a neutral screen.
Interference Phase
Participants were presented with two novel stimuli that
had to be ignored or updated according to the absence
or presence of the letter “T.” Updated stimuli displaced
the previous set of stimuli as the target stimuli. There was
also a control condition containing only a fixation cross
(no interference).
Probe Phase
A single stimulus was presented in the center of the
screen. Participants made a match or nonmatch response
with their middle or index finger. There was an equal
probability of the probe being a target or nontarget stim-
ulus. Half of nontarget stimuli were novel stimuli; the
other half were nontargets (dumped items in the update
condition or distractors in the ignore condition).
An interval of 2000 msec separated each trial. Partici-
pant’s block-wise accuracy was shown after each block.
Trials on which participants had to ignore or update in-
formation during the delay period were separated into
blocks to reduce task-switching effects and reduce the
possibility that the drug modulated performance by in-
creasing cognitive switching.
There were five runs in each session. Each run contained
four blocks (two update and two ignore blocks, order ran-
domized, nine trials per block). In each block, there were
three gain, three loss, and three neutral outcome trials,
during which they could gain, lose, or receive no money.
Our main index of behavior was accuracy. Accuracy
scores were arcsine transformed to conform to parametric
assumptions (Howell, 1997). This transform did not alter
the significance of the result.
fMRI Statistical Data Analysis
Data Acquisition
Participants were scanned at the Donders Centre for
Cognitive Neuroimaging using a Siemens Tim Trio 3-T
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Scanner. A multiecho EPI sequence was used to acquire
T2*-weighted images (repetition time=2.32, echo times=
9, 19.3, 30, and 40 msec, flip angle = 90°). Each run con-
sisted of 1360 (4 × 340 scans per echo) scans of 38 slices
(slice thickness = 2.5 mm, resolution = 3.3 mm× 3.3 mm×
2.5 mm). Thirty scans were acquired at the beginning of
each testing day to use as “weighing scans” (see below).
Participants were scanned using a 32-channel head coil.
Movement was minimized by positioning two cushions
to either side of the participant’s head and by placing
tape across participant’s forehead. Participants completed
five runs of the experimental task. A high-resolution struc-
tural scan of the brain was also acquired during the intake
session (MPRAGE: 192 scans, repetition time = 2300 msec,
echo time = 3.03 msec) to aid with preprocessing (see
below).
Data Preprocessing
Data were preprocessed in SPM5 using a pipeline opti-
mized for analyzing multiecho data (Poser, Versluis,
Hoogduin, & Norris, 2006) and was the same pipeline
as used previously (Fallon & Cools, 2014). This involved
using data from the first echo to estimate the six rigid
body realignment parameters (x, y, z, roll, pitch, yaw)
needed to align the images and applying these realign-
ment parameters to data from the other three echoes.
Correction for image misalignment was performed by
aligning the first image of all the subsequent runs to the
first image of the first run and then realigning each image
in each run to the first image in that run.
Images from the four echoes were then combined into
a single image as a weighted-sum of data from the four
echoes. On each testing day, 30 “weighing” scans were
acquired. This enabled us to perform a voxel-specific
weighing between the four echoes using in-house soft-
ware, which maximized the contribution of each echo ac-
cording to its contrast to noise ratio (see Poser et al.,
2006). The combined images were then slice-time cor-
rected to the middle slice, coregistered with participant’s
structural MPRAGE and then normalized to a standard
template (Montreal Neuroimaging Institute) using the
“unified segmentation” procedure (Ashburner & Friston,
2005). The data were smoothed with an 8-mm FWHM
Gaussian kernel.
Comparison of Movement across Drug Sessions
The absolute mean level of movement (mm) in the x, y,
z directions were .10, .12, and .36, respectively. The mean
angular movement (degrees) in the roll, pitch, and yaw
directions were .005, .004, and .003, respectively. Further-
more, there were no significant differences between the
placebo and drug sessions in the absolute level of move-
ment on any of these six metrics (all ts < 1).
Modeling
First-level Modeling
The following events were modeled: initial encoding
stimuli, “loss,” “neutral,” “win” screen, to-be-ignored
stimuli, fixation cross (no interference condition), to-be-
updated stimuli and probe event, and end of block
accuracy screen. In addition, parametric modulators,
orthogonalized to the task regressor, were entered for
the three working memory conditions (ignore, no interfer-
ence, and update) regressors. These regressors corre-
sponded to the valence of the received outcome on the
current trial (1 for loss, 2 for neutral and 3 for gain). This
modeling approach (Fallon & Cools, 2014) enabled us to
examine whether the response to the intervening stimuli
was modulated in a linear fashion by the valence of the
preceding outcome. Finally, a parametric regressor corre-
sponding to the RT for the probe event was added. All
task-related regressors were convolved with a canonical
hemodynamic response function. The first-level design
matrices were adapted to deal with nuisance variables in
the exact same way as our previous study (Fallon & Cools,
2014). Following the approach of Lund, Norgaard, Rostrup,
Rowe, and Paulson (2005), 24 nuisance regressors were
included in the model: the six realignment parameters
used to realign each image, the square of these realign-
ment parameters, the first derivative of these realignment
parameters, and the realignment parameters used to
realign the previous volume (to account for spin-history
effect; Friston, Williams, Howard, Frackowiak, & Turner,
1996). A high-pass filtered (128 sec) was applied to the data
to remove low frequency signals and an AR(1) model was
applied to adjust for serial correlations. Microtime onsets
were adjusted to take into account the earlier slice-timing
correction.
Second-level Modeling
This study aimed to investigate whether methylphenidate
modulates reward processing, working memory, and
their interaction. Accordingly, we built three full factorial
models to answer our principal questions. In all of these
models, regressor-based beta weight maps were passed
to the second level. Drug effects on the BOLD response
to intervening stimuli were examined in a 2 (update,
ignore) × 2 (drug, placebo) factorial model. Similarly,
drug effects on the outcome phase were examined by
entering contrast images (beta weights) into a 2 (gain,
loss) × 2 (methylphenidate, placebo) full factorial model.
Finally, task and valence interactions were examined in a
2 (parametric modulation of update response, parametric
modulation of ignore response) × 2 (drug, placebo) full
factorial model.
For each model, main effects of task, drug, and the in-
teraction between task and drug were evaluated using
F tests and followed up, where appropriate, with t test to
illustrate the direction of the effects. Random field theory
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was used to correct the p values at the voxel level for
multiple comparisons within our a priori generated ROIs.
ROI Selection
This experiment was designed to address the following
question: Does methylphenidate affect working memory
through acting on the dorsal striatum and/or pFC? This
question justified the use of an ROI approach. We gener-
ated ROIs directly based on independent data from our
previous study (Fallon & Cools, 2014), which used the
same task with the same parameters. For the model exam-
ining frontostriatal BOLD signal during the interference
phase, we composed an intervening stimulus-related ROI
that included the striatum (defined as regions significantly
activated, p < .01 for update minus ignore trials) and the
pFC (defined as regions significantly activated, p < .01 for
ignoreminus update trials). For the outcome phasemodel,
we generated an outcome-related ROI by comparing gain
minus loss events at the outcome phase in our previous
data ( p< .01, uncorrected). Previously we did not identify
a significant Reward × Task interaction and therefore had
no a priori predictions about the neural locus of this
contrast’s effects. Thus, it was not warranted to generate
an ROI for this contrast.
Data Visualization
Regions that showed statistically significant differences
between conditions (Figure 2B, C) were plotted using
rfxplot (rfxplot.sourceforge.net/) and displayed as per-
cent signal change: % signal change = (Beta(task) ×
max(HRF) × 100)/(Beta(constant)) (see Glascher, 2009,
for more details).
RESULTS
Behavioral Data
To compare the effect of drug on working memory as a
function of task demands and outcome valence, we ex-
amined accuracy scores using a Drug (methylphenidate,
placebo) × Task (ignore, no interference, update) Drug ×
Task × Reward (loss, neutral, or gain) repeated-measures
ANOVA. Methylphenidate differentially affected accuracy as
a function of task, as confirmed by a significant interaction
between task and drug (F(2, 40) = 20.16, p = .0000008;
Figure 2A). Simple main effects analysis revealed that this
was due to methylphenidate, relative to placebo, improv-
ing performance on ignore trials (F(1, 20) = 15.29, p =
.01) and no-interference trials (F(1, 20) = 10.72, p =
.04). In contrast, methylphenidate impaired performance
on update trials (F(1, 20) = 8.44, p= .0088). Furthermore,
follow-up tests revealed that methylphenidate, relative to
placebo, disproportionately improved performance on
ignore trials compared with no-interference trials (F(1,
40) = 5.43, p = .03). There was a significant main effect
of Task (F(2, 40) = 78.63, p = 1.4 × 10−14) but no sig-
nificant main effect of Drug (F(1, 20) = 1.83, p = .19) or
reward (F < 1). None of the other interaction effects
were significant (Fs < 1). Of note, accuracy for novel
Figure 2. Accuracy scores
(proportion correct) for
each task as a function of
drug (A). BOLD signal in the
left dorsolateral pFC
(B; x = −44, y = 18,
z = 38) and dorsomedial
pFC (C; x = −2 y = 38
z = 38) was significantly
modulated by drug
(methylphenidate) in a
task-specific (ignore
vs. update) manner. Bars
represent percent signal
change (see Methods
section for calculation)
with a 3-mm sphere around
the respective peak voxels
for the interaction between
task and drug. BOLD signal
during the no-interference
trials are shown for
illustrative purposes. For
comparison, BOLD signal
in the left dorsal striatum
(x = −18 y = 12 z = 4, 3 mm
sphere extracted from update
minus ignore) is shown (D).
In all graphs, error bars represent the standard error of the difference between methylphenidate and placebo according to each condition.
DLPFC = dorsolateral pFC; DMPFC = dorsomedial pFC.
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probes was significantly higher compared with those for
distracter probes in both the ignore (t(20) = 3.417, p =
.003) and update conditions (t(20) = 2.35, p = .029).
Thus, indicating that participants processed the distrac-
ters in the ignore condition and the initial targets in the
update condition. Moreover, there was no significant in-
teraction between Drug, Task, and Probe type or between
Drug and Probe type (Fs < 1). Further supplementary
analysis confirmed that there was no significant difference
in accuracy between the no-interference trials sandwiched
in the ignore blocks and those in the update blocks and
that performance on these trial types did not vary as a
function of drug (Fs < 1).
The same statistical model that was used to evaluate
accuracy was used to examine RT differences. This anal-
ysis revealed that there was a main effect of Task, F(2,
40) = 15.83, p = .000004. Pairwise comparisons revealed
that participants were significantly faster to respond on
update trials compared with ignore trials (t(19) = 4.67,
p = .00017) and no interference trials (t(19) = 4.50, p =
.00024). There was no difference in response latencies for
ignore and no interference trials (t(19) = .10, p = .91).
There was no significant interaction between Drug and
Task (F(2, 40) = 1.588, p= .217). None of the other effects
or interactions were significant (Fs < 1).
Neuroimaging Results
Interference Phase
Main effect of task. Consistent with our previous study
(Fallon & Cools, 2014), the intervening stimuli elicited
differential effects when they had to be ignored versus
used for updating in a variety of frontal, parietal, occipital,
and subcortical areas. Ignoring, relative to updating, was
found to lead to bilateral increases in the dorsolateral
pFC and posterior parietal cortex (angular gyri). In con-
trast, updating, relative to ignoring, was found to lead to
bilateral increases in the dorsal striatum and posterior
ventral areas extending from the inferior temporal gyri
to the occipital cortex (Table 1; Figure 3A).
Main effect of Drug. During the intervening stimuli, sig-
nificant ( p < .05, small volume-corrected) main (F test)
Table 1. Results Table for Directional Tests on the Interference Phase (t Test)
Contrast Regions
Number of
Voxels (k)
p (FWE, Small
Volume) t
MNI
Coordinates
(x y z)
Methylphenidate minus Placebo Dorsal caudate nucleus 23 .005 4.4 −16 0 14
Left putamen 3 .011 4.18 −24 2 −10
Left putamen 29 .039 3.76 −20 16 8
Placebo minus Methylphenidate Nothing
Ignore minus Update Left angular gyrus 557 <.0001 8.47 −58 −60 30
Left angular gyrus 74 <.0001 7.90 −40 −74 42
Left superior medial gyrus 62 <.0001 6.84 −6 42 38
Left middle frontal
gyrus
101 <.0001 6.22 −34 14 46
Right middle frontal gyrus 19 <.0001 5.88 38 16 44
Left precuneus 74 <.0001 5.45 52 −52 38
Update minus Ignore Left putamen 210 <.0001 5.68 −18 12 4
Right putamen 13 .046 3.70 20 14 2
Right putamen 1 .005 3.26 26 16 4
[Methylphenidate-ignore minus
Placebo-ignore] vs.
[Placebo-update minus
Methylphenidate]
Dorsomedial pFC 22 .003 4.63 −4 38 38
Left dorsolateral pFC 10 .021 3.96 −42 20 38
[Placebo-ignore minus
Methylphenidate] vs.
[Methylphenidate
minus Placebo-update]
None
Correction for multiple comparisons was performed voxel-wise random field theory within the task-related ROI.
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effects of Drug, irrespective of task demands, were found
in the dorsal caudate nucleus [x = −16, y = 0, z = 14]
and the left putamen [x = −24, y = 2, z = −10]. A
follow-up t test revealed that there was significantly in-
creased BOLD signal in the left posterior caudate nucleus
[x = −16, y = 0, z = 4], left ventral striatum [x = −24,
y = 2, z = −10], left dorsal striatum [x = −20, y = 16,
z = 8], right dorsal striatum [x = 24, y = 18, z = 2], and
posterior ventral striatum [x = −20, y = 4, z = 12] after
methylphenidate compared with placebo (Figure 4;
Table 1). There were no regions that showed significantly
greater BOLD signal in placebo compared with methyl-
phenidate (Table 1).
Drug × Task effects. In agreement with the behavioral
data, there was a significant interaction between Drug and
Figure 3. (A) Task-related
effects. Left: shown in cyan
are voxels that were significant
( p < .001, uncorrected) for
the update minus ignore
events collapsed across
methylphenidate and placebo
sessions. Right: shown in
yellow are voxels that were
significant ( p < .001,
uncorrected) for the update
minus ignore events collapsed
across methylphenidate and
placebo sessions. (B) Task-
and reward-related effects
within a mask of the basal
ganglia, collapsed across
placebo and methylphenidate
sessions. Shown in green are
significant voxels ( p < .001,
uncorrected) for the gain minus
loss events. Shown in cyan
are voxels that were significant
( p < .001, uncorrected) for
the update minus ignore
contrast. Note that we corrected
for multiple comparisons for
statistical inference (tables
and text) but display at an
uncorrected threshold to
illustrate the physiogical
plausibility of the effects.
Figure 4. Effect of
methylphenidate during the
interference period. Shown in
purple are the areas that
showed a task-general
response to methylphenidate
( p < .001, uncorrected,
F test for the main effects of
Drug for both ignore and
update trials). Shown in red
are the regions that showed
an interaction between Drug
and Task during the interference
phase (t contrast between
methylphenidate ignore minus
placebo ignore vs. placebo
update minus methylphenidate
update, p < .001, uncorrected).
Display at an uncorrected
threshold was chosen for
illustrative purposes, though note that the left dorsolateral pFC and dorsomedial pFC were significant after correcting for multiple comparisons
( p < .05, FWE, small volume-corrected).
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Task (update, ignore) in the brain (Figures 2B, C and 4).
Significant effects ( p < .05, FWE, voxel level, small
volume-corrected) on BOLD signal were observed in
the left dorsolateral pFC [x = −42, y = 20, z = 38] and
dorsomedial pFC [x = −4, y = 38, z = 38].
Follow-up t contrasts determined the direction of
these effects. Contrasting ignore minus update trials on
methylphenidate with update minus ignore trials on pla-
cebo revealed significantly ( p < .05, FWE, voxel level,
small volume-corrected) increased BOLD signal in the
left dorsolateral pFC [x = −44, y = 18, z = 38] and dor-
somedial pFC [x = −2, y = 38, z = 38] (Table 1). Spe-
cifically, methylphenidate, relative to placebo, increased
BOLD signal in the left dorsolateral pFC on ignore trials,
whereas there was no difference on update trials
(Figures 2B and 4). In contrast, methylphenidate, relative
to placebo, increased BOLD signal in the dorsomedial
pFC during ignore trials, but decreased BOLD signal dur-
ing update trials (Figures 2C and 4). The reverse contrast
(placebo ignore minus methylphenidate ignore, methyl-
phenidate update minus placebo update) did not pro-
duce any significant increases in BOLD signal.
Outcome Phase
For outcome, there were no main effects of Drug
(Table 2). There was a significant ( p < .05, FWE, small
volume-corrected) main effect of Outcome in the left ven-
tral striatum [x = −12, y = 0, z = −12]. Follow-up t con-
trasts determined the direction of this effect. Examining
gain minus loss events across both placebo and drug ses-
sions revealed significant ( p < .05, FWE, small volume-
corrected) BOLD signal in the bilateral ventral striatum
[x = 10, y = 4, z = −12], [x = −12, y = 0, z = −12]
(Table 2; Figure 3B). In line with the lack of a behavioral
interaction between drug and outcome, there was no
significant ( p < .05, FWE, small volume-corrected) inter-
action between Methylphenidate and Outcome (Table 2).
Parametric Modulation of Task by Preceding
Outcome Valence
We also investigated whether the neural response to
each task condition (ignore or update) was modulated
in a parametric (linear) fashion according to the valence
of the preceding outcome delivery. In other words, we
asked whether the BOLD response to ignore or update
events increased linearly as a function of reward level.
In line with the lack of interaction between Drug, Task,
and Outcome at the behavioral level, there were no sig-
nificant voxels ( p < .05, FWE whole brain) for the three-
way interaction between drug, task, and outcome, that is,
there were no significant voxels whose response to the
task (ignore, update) varied parametrically according to
the preceding valence and drug.
Other Phases of the Task
To examine whether methylphenidate also had an effect
during encoding and probe, we compared the BOLD sig-
nal on methylphenidate and placebo for these two
events. There was no significant ( p < .05 FWE) voxels
in either the encoding or the probe phase within our
task-related ROI or even at the whole-brain level.
Brain–Behavioral Analyses
Correlational analyses revealed that the methylphenidate-
induced improvement in accuracy on ignore trials was
related to the corresponding methylphenidate-induced
increase in BOLD signal in the left dorsolateral pFC
(3 mm sphere around the peak voxel for the interaction
between Drug and Task: x = −44, y = 18, z = 38) during
ignore trials (rho(21) = .551, p= .009; Figure 4). However,
there was no relationship between the methylphenidate-
induced change in the left dorsolateral pFC during update
Table 2. Results Table for Directional Comparisons in the Outcome Phase (t Test)
Contrast Regions
Number of
Voxels (k)
p (FWE, Small
Volume-corrected) t
MNI Coordinates
(x y z)
Win minus Loss Left ventral striatum 27 .024 3.98 −12 0 −12
Right ventral striatum 37 .035 3.86 10 4 −12
Loss minus Win No regions contained within ROI
Methylphenidate minus Placebo No regions contained within ROI
Placebo minus Methylphenidate No regions contained within ROI
Methylphenidate win minus Placebo
win vs. Placebo loss minus
Methylphenidate loss
No regions contained within ROI
Placebo win minus Methylphenidate
win vs. Methylphenidate loss
minus Placebo loss
No regions contained within ROI
Correction for multiple comparisons was performed voxel-wise random field theory within the task-related ROI.
Fallon et al. 659
trials and change in behavioral performance (rho(21) =
.005, p = .984). There was no significant correlation be-
tween methylphenidate-induced changes in BOLD signal
in the dorsomedial pFC (3 mm sphere at around: x =
−2, y = 38, z = 38) and behavior for ignore trials (rho
(21) = −.159, p = .491) or update trials (rho(21) =
−.104, p= .652). Similarly, there was no significant associ-
ation between the effect of methylphenidate-induced
changes in BOLD signal in the left dorsal striatum and ig-
noring (rho(21) = .190, p = .490) or updating (rho(21) =
−.240, p = .295). Finally, there was no significant correla-
tion between the effect of methylphenidate on ventral
striatal BOLD response to outcome ([methylphenidate
gain minus methylphenidate loss vs. placebo gain minus
placebo loss]) and change in behavior in the ignore
(rho(21) = .197, p= .392) or update conditions (rho(21) =
−.022, p= .92).
DISCUSSION
The present results demonstrate that methylphenidate
improves distractor resistance at the expense updating.
Thus, across-subject, drug-induced gains in ignoring in-
terfering information were partially offset by an impaired
ability to use this information to update current working
memory representations.
Methylphenidate is commonly regarded as a cognitive
enhancer, because it can improve certain functions
(Elliott et al., 1997). In this study, however, methylpheni-
date did not act as a uniform cognitive enhancer. Instead,
it improved cognitive stability at the expense of cognitive
flexibility. Therefore, the present findings show that
methylphenidate is a double-edged sword, that is, meth-
ylphenidate’s beneficial cognitive effects come at a cost.
In addition to examining the differential cognitive ef-
fects of methylphenidate, this study also sought to adju-
dicate between competing accounts of the neural locus
of these effects. The balance between cognitive stability
and cognitive flexibility in working memory has been
argued to be regulated by dopamine in frontal (Fallon,
Williams-Gray, Barker, Owen, & Hampshire, 2013;
Durstewitz & Seamans, 2008; Rolls, Loh, Deco, & Winterer,
2008) and striatal brain regions (Cools & D’Esposito, 2011;
Hazy et al., 2007). Our fMRI results serve to unify seemingly
contradictory and disparate reports on the neural basis of
catecholamine-induced cognitive changes by showing that
task-specific and task-general effects of methylphenidate
are distributed between the frontal cortex and the striatum
respectively. The contrasting effects of methylphenidate on
working memory were associated with contrasting effects
on the pFC. Specifically, methylphenidate increased BOLD
signal in the left dorsolateral pFC and the dorsomedial pFC
during ignore trials, while decreasing BOLD signal in the
dorsomedial pFC during update trials (Figures 2B–C and 4).
This finding concurs with prior observations that catechol-
amines can act directly on the pFC to elicit adaptive dynam-
ics of cognitive control (Berridge & Arnsten, 2015; Ott,
Jacob, & Nieder, 2014; Floresco, 2013; Arnsten & Dudley,
2005), for example, by modulating short-term synaptic plas-
ticity (Stokes et al., 2013; Mongillo, Barak, & Tsodyks, 2008;
Gonzalez-Burgos, Kroener, Seamans, Lewis, & Barrionuevo,
2005). Moreover, neurons in this region have been found
to be exquisitely sensitive to the neurochemical niche they
occupy (Seamans & Yang, 2004; Williams & Goldman-Rakic,
1995). Specifically, our effects might be captured by dual-
state theory (Durstewitz & Seamans, 2008), a recurrent
network model of pFC dynamics, grounded in neurophys-
iology, according to which dopamine contributes critically
to flexible transitions between different network states in
the pFC. In this model, pFC networks can be either in a
D1-dominated state, associated with intermediate levels of
dopamine, which is characterized by a high-energy barrier fa-
voring robust stabilization of representations, or in a D2-
dominated state, associated with (low or) high levels of
dopamine, which is characterized by a low-energy barrier
favoring fast, flexible shifting between representations. Here
methylphenidate modulated BOLD signal in prefrontal
regions, improving cognitive stability but impairing cognitive
flexibility. As such, the present results are consistent with the
idea that methylphenidate exerts its therapeutic cognitive
effects by acting on the pFC (Spencer, Klein, & Berridge,
2012; Berridge et al., 2006; Arnsten & Dudley, 2005).
In addition to observing task-specific effects in the
pFC, we also observed task-general effects in the stria-
tum. Methylphenidate potentiated BOLD signal in the
striatum during the intervening stimulus across all three
(ignore, no interference, and update) working memory
conditions. Importantly, methylphenidate did not induce
these changes during any of the other task phases (en-
coding, outcome, or probe), suggesting that the effects
were specific to the processing of novel, intervening sa-
lient stimuli or events, irrespective of their visual features
or cognitive requirements, that is, the BOLD response for
to-be-ignored stimuli, to-be-updated stimuli, and fixation
crosses were all enhanced after methylphenidate admin-
istration. This is consistent with current ideas about stria-
tal dopamine’s role in the processing of salience
(Redgrave & Gurney, 2006) and in registering changes
in the environment that may require changes in atten-
tional selection (van Schouwenburg, den Ouden, &
Cools, 2010). It is possible that the changes we observed
in the striatum could have been a necessary precondition
for effects at the pFC to arise. Indeed, methylphenidate’s
therapeutic and cognitive effects have repeatedly been
shown to be a function of the degree to which methylphe-
nidate increases striatal dopamine release (Clatworthy
et al., 2009; Volkow, Wang, Fowler, & Ding, 2005). In keep-
ing with this striatal facilitation hypothesis, there is a rich
set of reciprocal interactions between frontal and striatal
areas, with the timbre of this relationship strongly influ-
enced by dopamine levels in the respective areas. For ex-
ample, impaired functioning of the frontal cortex and/or
prefrontal dopaminedepletion are known to lead to changes
in striatal dopamine transmission (Meyer-Lindenberg et al.,
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2002, 2005; Roberts et al., 1994; Louilot, Le Moal, & Simon,
1989; Pycock, Kerwin, & Carter, 1980). Conversely, changes
in striatal dopamine levels and dopamine D1 receptor func-
tion have been found to alter cortical dynamics (Cole et al.,
2013; Dang, O’Neil, & Jagust, 2012; Braskie et al., 2011;
Rieckmann, Karlsson, Fischer, & Backman, 2011;
Kellendonk et al., 2006). Thus, frontal responses, and their
behavioral consequences, can vary according to striatal
dopamine transmission. On the basis of these findings,
one might hypothesize that the methylphenidate-induced
changes in the striatum played a causal role in promoting
the changes we observed in the frontal cortex. Of course,
the current data do not provide empirical evidence for this
speculation, and future work is required to test directly this
alternative striatal hypothesis.
The effects of methylphenidate on working memory
and associated neural responses did not vary with the va-
lence of the preceding outcome, although this paradigm
successfully elicited reward-related increases in ventral
striatal BOLD signal. Given the association between
methylphenidate and motivation, such a modulation by
stimulants may only occur when gains or losses are con-
tingent upon performance, that is, when the potential
financial gains/losses are contingent upon performance
of certain task (Wardle, Treadway, & de Wit, 2012). There
is clearly a pressing need for future studies to investigate
this question. As such, the possibility that methylpheni-
date acts vicariously to boost cognitive function through
enhancing motivation remains open.
There are a number of caveats and issues in need of
explanation. One might argue that the differential effect
of methylphenidate on ignoring and updating occurred
because the updating task was easier than the ignoring
task. For example, in the ignore condition, information
had to be maintained for a longer period than the update
task. Several aspects of the present result make it ex-
tremely unlikely that differential demands for maintenance
underlie our drug-induced effects at the behavioral or neu-
ral level. First, with regard to behavior, the maintenance
periods for the ignore and no-interference conditions were
identical. Despite this, methylphenidate, compared with
placebo, had differential effects on accuracy in the ignore
and no-interference conditions, indicating that methylphe-
nidate acted on the specific process of distractor resis-
tance. Moreover, the accuracy rates for the ignore and
no-interference conditions were identical for the placebo
session, arguing against the idea that there was any base-
line difference in intrinsic difficulty. With regards to the
neural data, it should be noted that, at the point at which
new information (or fixation cross) was being presented to
participants, the maintenance periods for the preceding
stimuli in each of the three conditions (ignore, no inter-
ference, and update) were the same. Thus, none of the
neural data on drug-induced effects at the interference
phase could have been affected by differences in the
maintenance period. Moreover, methylphenidate had op-
posite effects on prefrontal BOLD signal during ignoring
versus updating (Figure 2B–C). Thus, despite all of the
preceding experimental events and durations being identi-
cal up until the point of the interference phase, differences
in drug-induced neural signaling were observed between
the conditions at the very first point were the conditions
started to diverge in their psychological requirements.
However, further work is necessary to fully characterize
the role of difficulty (or mental effort) in the effects of meth-
ylphenidate on ignoring and updating. Specifically, future
experiments should vary the set size of the number of items
that need to be maintained, ignored, and updated. This
would be a most elegant way to disentangle task difficulty
and intrinsic differences associated with having to ignore
versus update information in working memory.
Our hypotheses are grounded in computational and
theoretical work on the dopamine system. However,
we cannot or do not claim an exclusive, or even decisive,
role for dopamine in generating the present findings. For
example, methylphenidate is known to affect noradrena-
line levels in the pFC (Berridge et al., 2006). Therefore, it
is possible that methylphenidate’s effects on frontal
signaling observed in this study are mediated by nor-
adrenaline. As is the case for dopamine, optimal levels
of noradrenergic stimulation are necessary for working
memory performance and dynamic cognitive control
(Arnsten, 2011; Aston-Jones & Cohen, 2005). Thus, fur-
ther studies are needed to determine the pharmacologi-
cal specificity of these effects both with regard to both
the neurotransmitters as well as the receptor subtypes.
This study has important implications for the use of
methylphenidate as a cognitive enhancer in normal
healthy individuals. Methylphenidate is commonly used
as a treatment for ADHD, but a growing proportion of
healthy individuals are taking this drug to improve cogni-
tive performance (Greely, 2013). The present results sug-
gest that methylphenidate does not act as a “smart pill”:
Taking methylphenidate does not make an individual
smarter. Rather, in agreement with its known neuro-
chemical effects, that is, boosting catecholamine levels,
methylphenidate’s enhancement of a cognitive function
comes at the cost of impairing other cognitive functions.
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